Life Sciences

  • May 05, 2026

    Sanofi Unit Gets Backup In Fed. Circ. Double Patenting Appeal

    Canon, Sonos and several other tech and biopharma companies have thrown their weight behind a Sanofi subsidiary's appeal challenging how the Patent Trial and Appeal Board handles obviousness-type double patenting.

  • May 05, 2026

    ERISA Recap: 5 Litigation Developments From April

    The U.S. Supreme Court turned down a bakery company's bid for review of a union multiemployer pension withdrawal bill, the Fourth Circuit held a bonus plan was exempt from federal benefits law, and the Sixth Circuit ruled federal law preempted Arkansas pharmacy benefit manager laws and regulations. Here's more on those and two other major decisions from April that benefits attorneys may want to know.

  • May 05, 2026

    Apple Urges Full Fed. Circ. To Undo Original Watch Import Ban

    A Federal Circuit panel erred when finding the U.S. International Trade Commission properly banned imports of Apple Watches with blood oxygen-monitoring features, the tech giant behind the devices said in a plea for rehearing by the full court.

  • May 05, 2026

    $100M AI Investment Suit Must Be Arbitrated, Financier Says

    A California financier Tuesday denied allegations in a $100 million fraud lawsuit over a "sham" loan transaction aimed at funding an investment into an artificial intelligence company, adding that the dispute belongs in arbitration in the Bahamas.

  • May 05, 2026

    Mylan Strikes $4.5M Deal With Maryland Over EpiPen Pricing

    Mylan Pharmaceuticals will pay $4.5 million to resolve allegations by the state of Maryland that Mylan acted anticompetitively when it ratcheted up costs of its portable auto-injectable EpiPen device that's used during life-threatening allergic reaction episodes, according to a recent announcement.

  • May 05, 2026

    4th Circ. Backs Raytheon In Ex-Workers' Vaccine Bias Case

    The Fourth Circuit upheld RTX Corp.'s defeat of a lawsuit claiming it forced out employees who received religious exemptions to its COVID-19 vaccine policy, ruling Tuesday that the ex-workers behind the suit filed their claims too late.

  • May 05, 2026

    Amylyx Investors To Get $6.5M In ALS Drug Settlement

    Amylyx Pharmaceuticals and a class of shareholders are seeking judicial approval for a $6.5 million settlement to resolve allegations that the drugmaker overstated the commercial potential of a treatment for amyotrophic lateral sclerosis, or ALS, that was ultimately shelved.

  • May 05, 2026

    CooperSurgical Strikes Deal To End Embryo Loss Class Suit

    Connecticut-based fertility products manufacturer CooperSurgical Inc. has reached a settlement with a proposed class of in vitro fertilization patients and their partners, who claimed the company's defective product caused the loss of their embryos.

  • May 05, 2026

    Sandoz, Novartis Must Face Generics Claims From GM, Others

    A Pennsylvania federal judge largely refused to let dozens of generic-drug makers duck stand-alone price-fixing and market allocation antitrust claims from major employers like General Motors, American Airlines and Lowe's, nixing allegations against a small handful while importantly preserving them against Novartis and its former Sandoz subsidiary.

  • May 05, 2026

    Deutsche, Pathward Want Fintech Blacklist Suit Tossed

    Deutsche Bank AG and Pathward NA urged a New York federal court to dismiss a suit accusing them of improperly blacklisting a barter-based payment platform that the banks found was "transaction laundering" for companies selling gray-market pharmaceuticals, arguing that the suit's jurisdiction assertions are fatal to the claims.

  • May 05, 2026

    Travelers Unit Says No Coverage In Cannabis Explosion Suits

    A Travelers Property Casualty Corp. unit is suing two of its insureds in California federal court, seeking a declaration that its insurance policies don't cover defense and indemnity of suits over a deadly explosion allegedly caused by an illegal cannabis operation.

  • May 04, 2026

    'They Knew It': J&J Accused Of Hiding Talc Risk At LA Trial

    Johnson & Johnson knew for decades that its baby powder contained asbestos, even as it advertised the product as safe and "pure," attorneys for the families of three women who died of ovarian cancer told a California jury Monday during opening statements in a bellwether trial.

  • May 04, 2026

    Biotech Overhyping Obesity Drug Hurt Investors, Suit Says

    Current and former executives of drugmaker Skye Bioscience Inc. breached their fiduciary duties by overstating an obesity drug's clinical prospects and precipitating a trading price decline when the company revealed disappointing study results, an investor has alleged.

  • May 04, 2026

    Judge Shuts Down Invalidity Theory In Abiomed IP Case

    A Massachusetts federal judge has foreclosed one of Abiomed's invalidity defenses in a case brought by rival medical technology firm Maquet over alleged infringement of a patent covering blood pump technology.

  • May 04, 2026

    Supplement Co. Says False Labeling Plaintiff Never Saw Ads

    The maker of Thesis Nootropics supplements is asking a New York federal court to throw out claims that it falsely advertises its products as ADHD medications, saying the plaintiff hasn't sufficiently alleged she ever saw the advertisements or even used the products.

  • May 04, 2026

    Supreme Court Halts Abortion Drug Telehealth Ruling

    The U.S. Supreme Court on Monday temporarily reinstated telehealth access for the abortion medication mifepristone, pausing a lower-court order that had blocked by-mail and remote prescriptions.

  • May 04, 2026

    Justices Won't Hear Anti-Vaxxer Medical Board Suit

    The U.S. Supreme Court on Monday said it will not review a petition brought by Health and Human Services Secretary Robert F. Kennedy Jr. on behalf of doctors who challenged a Washington state medical board's investigation into an alleged COVID-19 misinformation campaign.

  • May 01, 2026

    Pharma Aims Torpedo At FCA After Bombshell 9th Circ. Ruling

    A burgeoning campaign against the False Claims Act's whistleblower mechanism is suddenly center stage at the Ninth Circuit, where pharmaceutical companies say a momentous new ruling "illustrates perfectly" the constitutional concerns of U.S. Supreme Court justices regarding FCA enforcement.

  • May 01, 2026

    Judge, Atty Get In Shouting Match At Fatal Overdose Trial

    Tensions boiled over in a Philadelphia courtroom Friday at the end of an emotionally fraught trial over a man's fatal opioid overdose, with a judge and lawyer shouting at each other about how to figure out an inconclusive verdict spurred by a seemingly confused juror.

  • May 01, 2026

    Twist Bioscience Investors Seek $17M Stock Fraud Deal OK

    Twist Bioscience Corp. and two executives asked a California federal court to give preliminary approval to a $17 million deal they inked with investors to resolve class allegations the company misrepresented that its technology could produce synthetic DNA at higher quality and lower cost than competitors.

  • May 01, 2026

    Amazon Accused Of Selling Kids Sunscreen With Lead

    Consumers on Thursday hit Amazon with a proposed class action in Washington federal court alleging that children's sunscreens it sells are contaminated with heavy metals such as lead and that its artificial intelligence shopping assistant Rufus doesn't disclose details about the product ingredients.

  • May 01, 2026

    Fla. Jury Hears Menthol Smoker Succumbed To Addiction

    A Florida jury heard in opening arguments Friday that a woman who died of lung cancer after smoking R.J. Reynolds cigarettes was a victim of the severely addictive nature of nicotine, something her lawyers said even the U.S. surgeon general didn't acknowledge until 1988.

  • May 01, 2026

    Texas High Court Revives Delta-8 THC Restrictions

    The Lone Star State's health commissioner has the power to ban manufactured delta-8 THC goods, the Texas Supreme Court ruled Friday, lifting a lower court's order that had allowed hemp companies to keep selling these products while they sued the state.

  • May 01, 2026

    Biotech IPOs Surge Ahead As 2 Listings Raise $557M

    A pair of biotechnology firms began trading on Friday after raising a combined $557 million through upsized initial public offerings that both priced at the top of their proposed $16 to $18 ranges, marking the latest drug developers to join the IPO market in recent weeks.

  • May 01, 2026

    5th Circ. Pauses Mail-Order Access To Abortion Pills

    The Fifth Circuit on Friday reinstated an in-person dispensing requirement for the abortion medication mifepristone, blocking mail-order access while a challenge to a Biden administration regulation brought by Louisiana officials moves forward.

Expert Analysis

  • Series

    Adapting To Private Practice: 5 Tips From Ex-SEC Unit Chief

    Author Photo

    My move to private practice has reaffirmed my belief in the value of adaptability, collaboration and strategic thinking — qualities that are essential not only for successful client outcomes, but also for sustained professional satisfaction, says Dabney O’Riordan at Fried Frank.

  • 5 Drug Pricing Policy Developments To Watch In 2026

    Author Photo

    2026 may prove to be a critical year for drug pricing in the U.S., with potential major shifts including several legislative initiatives moving forward after being in the works for years, and more experimentation on the horizon concerning GLP-1s and Section 340B pricing, say attorneys at Manatt.

  • Patent Applicants Must Get Biologics Enablement Right

    Author Photo

    As artificial intelligence increasingly becomes a core driver in drug discovery, it is critical for drug companies to adapt their drafting strategies to the unique features of AI-generated inventions, and to pay particularly close attention to enablement standards, says Sanandan Malhotra at Novo Nordisk.

  • Series

    Law School's Missed Lessons: How To Start A Law Firm

    Author Photo

    Launching and sustaining a law firm requires skills most law schools don't teach, but every lawyer should understand a few core principles that can make the leap calculated rather than reckless, says Sam Katz at Athlaw.

  • Fed. Circ. Patent Decisions In 2025: An Empirical Review

    Author Photo

    In 2025, the Federal Circuit's increased output was not enough to keep up with its ever-growing patent case load, and patent owners and applicants fared poorly overall as the court's affirmance rate fell, says Dan Bagatell at Perkins Coie.

  • Regulatory Uncertainty Ahead For Organ Transplant System

    Author Photo

    Pending court cases against a Centers for Medicare and Medicaid Services final rule that introduced a competition-centric model for assessing organ procurement organizations' performance will significantly influence the path forward for such organizations and transplant hospitals, say attorneys at Crowell & Moring.

  • Key False Claims Act Trends From The Last Year

    Author Photo

    The False Claims Act remains a powerful enforcement tool after some record verdicts and settlements in 2025, and while traditional fraud areas remain a priority, new initiatives are raising questions about its expanding application, says Veronica Nannis at Joseph Greenwald.

  • Opinion

    It's Too Soon To Remove Suicide Warnings From GLP-1 Drugs

    Author Photo

    The U.S. Food and Drug Administration's decision this month to order removal of warnings about the risk of suicidal thoughts from GLP-1 weight-loss drugs is premature — and from a safety and legal standpoint, the downside of acting too soon could be profound, says Sean Domnick at Rafferty Domnick.

  • Series

    Hosting Exchange Students Makes Me A Better Lawyer

    Author Photo

    Opening my home to foreign exchange students makes me a better lawyer not just because prioritizing visiting high schoolers forces me to hone my organization and time management skills but also because sharing the study-abroad experience with newcomers and locals reconnects me to my community, says Alison Lippa at Nicolaides Fink.

  • FDA's 2025 Enforcement Scorecard Highlights Data Focus

    Author Photo

    The U.S. Food and Drug Administration's increased enforcement activity in 2025 was driven by artificial intelligence and a focus on foreign manufacturers, necessitating proactive compliance strategies for an environment that is increasingly reliant on data, say attorneys at Reed Smith.

  • How A 1947 Tugboat Ruling May Shape Work Product In AI Era

    Author Photo

    Rapid advances in generative artificial intelligence test work-product principles first articulated in the U.S. Supreme Court’s nearly 80-year-old Hickman v. Taylor decision, as courts and ethics bodies confront whether disclosure of attorneys’ AI prompts and outputs would reveal their thought processes, say Larry Silver and Sasha Burton at Langsam Stevens.

  • Navigating Privilege Law Patchwork In Dual-Purpose Comms

    Author Photo

    Three years after the U.S. Supreme Court declined to resolve a circuit split in In re: Grand Jury, federal courts remain split as to when attorney-client privilege applies to dual-purpose legal and business communications, and understanding the fragmented landscape is essential for managing risks, say attorneys at Covington.

  • How AI Drafting Should Transform Patent Filing Strategies

    Author Photo

    As agentic artificial intelligence reduces the time and expense required to draft and file patents, companies should shift focus away from rationing drafting hours and more toward governing optionality, says Ian Schick at Paximal.

  • 5 Advertising Law Trends That Will Shape 2026

    Author Photo

    The legal landscape for advertisers will grow only more complex this year, with ongoing trends including a federal regulatory retreat, more aggressive action by the states, a focus on child privacy and expanded scrutiny of "natural" claims, say attorneys at Reed Smith.

  • Cannabis Industry Faces An Inflection Point This Year

    Author Photo

    Cannabis industry developments last year — from the passage of a new wholesale tax in Michigan, to an executive order accelerating the federal rescheduling process — presage a more mature phase of legalization this year, with hardening expectations and enforcement to come, says Alex Leonowicz at Howard & Howard.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.